2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Bioinformatics, Emerging Technologies, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Adverse Events, Artificial Intelligence (AI), Generative AI, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Value, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, CLL, Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult
PAPER

2645 Socioeconomic differences in chronic lymphocytic leukemia (CLL): Prescription trends of targeted therapeutics from 2016-2024

Joanna M Rhodes, MD, MSCE, Alice Wang, PhD2, James L Fisher, PhD3, Debbie Adkins, PhD, CStat4, Julia Ma, MPH5, Sarah Castro6, Maria Munoz-Sagastibelza, PhD7, Kristen Battiato8, Chang woo Han, PharmD9, Adam Kittai, MD10
1 Rutgers Cancer Institute, New Brunswick, New Jersey, United States
2 AstraZeneca, Gaithersburg, Maryland, United States
3 The Ohio State University, Columbus, Ohio, United States
4 AstraZeneca, Cambridge, United Kingdom
5 AstraZeneca, Mississauga, Canada
6 CLL Society, Chula Vista, California, United States
7 AstraZeneca, Gaithersburg, Maryland, United States
8 AstraZeneca, Gaithersburg, Maryland, United States
9 AstraZeneca, Gaithersburg, Maryland, United States
10 New York University Langone Health, Mineola, New York, United States

Introduction: Over the last decade, the treatment landscape for CLL/SLL has shifted away from chemoimmunotherapy (CIT) to targeted agents (TA) such as Bruton’s tyrosine kinase inhibitors (BTKi) due to improvements in outcomes and tolerability1. The NCCN guidelines are updated regularly to reflect these advances. Key updates included a preference for ibrutinib treatment in 2016, addition of acalabrutinib and venetoclax-obinutuzumab in 2019, and preference for second generation BTKi in 2023. While inequities in mortality in CLL/SLL due to socioeconomic status (SES) have been previously documented2, there is a lack of understanding on why these disparities exist. Given expense of TA, we hypothesized that areas of lower SES may receive TA at a lower rate than areas of higher SES, and this may impact OS and be a cause of the disparity in outcomes observed in CLL/SLL.   

Methods: To assess impact of SES on differences in prescription trends for TAs in CLL/SLL, we analyzed IQVIA claims data for patients with CLL who are 18+ at diagnosis with 2+ claims with diagnosis codes C91.1 or C83.0 on separate dates, and with a known US residential geographic ZIP code.  This cohort was additionally filtered on patients who had at least one targeted therapy and/or chemotherapy between 01/01/2016 and 03/21/2025 and did not have systemic cancer therapy before their CLL diagnosis. We excluded patients with allogenic HSCT. We used ZIP Code Tabulation Areas (ZCTA) to ascertain individual Social Deprivation Indices (SDI) assigned to each ZIP code and created quartiles based off our patient population. We also looked at year at treatment initiation. The primary objective of this study was to look at differences in treatments for patients based on their SES. A secondary objective was to look at the trend of receipt of NCCN recommended treatments by ZIP code and SES.

Results: 90,957 patients meeting inclusion criteria were included in the analysis. For first-line (1L) treatment, median age was 67 (range 18-88), 61.7% (56,100) were male, 22.8% (20,724) were located in north central US, 15.8% (14327) in northeast, 38.6% (35,029) south, and 22.8% (20,716) west. Median social deprivation index (SDI) score was 53 (range 1-100). 39.5% (35,908) initiated treatment in 2016, 11% (10,043) in 2017, 9.3% (8,500) in 2018, 8.7% (7,889) in 2019, 8.1% (7,353) in 2020, 7.6% (6,877) 2021, 6.3% (5,723) in 2022, 5.3% (4,808) in 2023, and 3.7% (3349) in 2024. 7.1% (6,429) of patients initiated 1L with chemotherapy, 9.6% (8,774) with CIT, 20.7% (18,845) with monoclonal antibody (mab) alone, 62.3% (56,704) with TA and 0.2% (187) with TA+mab. Common 1L treatments included 12.7% (11,559) acalabrutinib, 6.6% (5,980) bendamustine-rituximab, 33.8% (30,719) ibrutinib, 10.7% (9,706) venetoclax, 5.1% (4,657) zanubrutinib. CIT was given more frequently as 1L treatment in 2016 [14.3% (1,702)] and decreased over time with 498 pts (5.1%) in 2024. As chemotherapy use decreased, TA as single agents and in combination increased [49.0% (5,828) in 2016 to 68.5% (6,661) in 2024]. After 2019, use of ibrutinib as 1st TA decreased as use of other TA increased: in 2019, 53.2% of patients on active treatment received ibrutinib as their initial treatment, while 9.4% received other TAs; in 2024, 7.3% and 61.2% of patients received ibrutinib and other TAs as initial treatment, respectively. Treatment type by SDI was not significantly different for 1L chemotherapy (Q1 16.6% - Q4 17.4%), ibrutinib, acalabrutinib, zanubrutinib or venetoclax (Q1-Q4, 32.2-34.6%, 12.6-12.7%, 5.3-4.6%, 8.8-8.4%, respectively) and did not differ based on treatment initiation year. Unadjusted logistic regression analyses for age, region, SDI quartile, presence of poverty, single parent household, education, home rental, home crowding, and unemployment did not show a statistically significant association with administration of chemotherapy as 1L therapy compared to TA.    

Discussion/Conclusions:  

To our knowledge, this is the first study to examine ZIP code to ascertain differences in 1L treatment for CLL/SLL based on SES. Our data demonstrates adoption of TA based therapies aligned with when they were added to the NCCN guidelines, with receipt of 2nd generation cBTKi increasing over time. Additionally, SDI scores were not associated with receipt of CIT for 1L treatment of CLL/SLL. These data highlight that SES does not appear to influence treatment selection for patients with CLL/SLL.

 

Joanna M Rhodes, MD, MSCE: Acrotech - Research Funding; Acerta - Research Funding; Janssen - Research Funding; Beigene - Research Funding; Merck - Research Funding; Oncternal - Research Funding; AstraZeneca - Research Funding; Epizyme - Research Funding; ADC Therapeutics - Research Funding; Loxo Oncology - Research Funding; Velosbios - Research Funding; Abbvie - Research Funding; BeOne - Research Funding; Johnson and Johnson - Research Funding; Morphosys - Consultancy (Includes expert testimony); Loxo Oncology - Consultancy (Includes expert testimony); Johnson and Johnson - Consultancy (Includes expert testimony); GenMab - Consultancy (Includes expert testimony); Pharmacyclics - Consultancy (Includes expert testimony); Genentech - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony); BeOne - Consultancy (Includes expert testimony); Janssen - Consultancy (Includes expert testimony); Eli Lilly - Consultancy (Includes expert testimony); Pharmacyclics - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Epizyme - Consultancy (Includes expert testimony); Abbvie - Consultancy (Includes expert testimony); ADC Therapeutics - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); Beigene - Consultancy (Includes expert testimony); SeaGen - Consultancy (Includes expert testimony)